Isoform Oncology discovers and targets cancer‑specific protein isoforms created by abnormal RNA splicing, developing antibody‑based biologics that bind these unique tumor‑restricted epitopes. Their platform integrates genomics, transcriptomics, and protein modeling to design isoform‑selective therapeutics that kill cancer cells while sparing normal tissue, addressing unmet needs in resistant and hard‑to‑treat cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often fail to target disease-specific protein variants that arise from alternative RNA splicing, leading to reduced efficacy and resistance in patients whose tumors express unique isoforms.
Solution
Isoform Oncology focuses on identifying cancer‑specific protein isoforms generated by aberrant splicing and developing biotherapeutics that selectively bind these variants. By exploiting isoform switching, the company creates antibodies or other biologics that recognize tumor‑restricted epitopes, enabling precise killing of cancer cells while sparing normal tissue. Their pipeline targets cancers with high unmet need where conventional treatments have limited success, aiming to provide on‑target, on‑time therapeutic action for patients lacking suitable options.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking novel, precision‑medicine biologics for oncology, as well as clinical research organizations developing therapies for splice‑variant driven cancers.
Features
- Systematic discovery platform that maps alternative splicing events across tumor types to pinpoint disease‑specific isoforms
- Computational pipeline integrating genomics, transcriptomics, and protein modeling to design isoform‑selective antibody candidates
- Biologics engineered for high affinity to unique splice‑variant epitopes, reducing off‑target toxicity
- Preclinical validation workflow that assesses isoform expression, target engagement, and tumor cell killing in resistant cancer models
- Modular development approach allowing rapid expansion of the isoform‑targeting portfolio across multiple cancer indications